JILL MILLER: Open Payments
NPI 1710612635 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,434 in 62 payments from 21 companies in 2025. Trend: 2023 $934 · 2024 $1,702 · 2025 $1,434
Food & beverage: $1,389Education: $45
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 13 | $249 |
| ABBVIE INC. | 14 | $238 |
| Novo Nordisk Inc | 5 | $160 |
| Axsome Therapeutics, Inc. | 2 | $136 |
| Vanda Pharmaceuticals Inc. | 4 | $115 |
| Teva Pharmaceuticals USA, Inc. | 3 | $77 |
| Indivior Inc. | 2 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Lundbeck LLC | 3 | $48 |
| Lilly USA, LLC | 1 | $45 |
Products named: VRAYLAR, Ozempic, Briviact, Auvelity, FANAPT, Fintepla, REXULTI, SUBLOCADE.
Industry payments across CA — which companies pay providers there.
